Imigran S.C. (Sumatriptan)

Sumatriptan binds to 5‑HT1B and 5‑HT1D receptors, causing constriction of intracranial blood vessels and blocking the release of inflammatory neuropeptides, which together interrupt the migraine cascade.

The prescribed dose of Imigran S.C. is determined by the treating physician based on the patient’s clinical condition and response; dosing instructions are not provided here.

Safety of sumatriptan in pregnancy and lactation has not been fully established. Prescribers should weigh potential benefits against risks and consider alternative therapies when appropriate.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Imigran S.C. is a rapid‑acting injectable triptan, offering faster onset than oral tablets. Compared with other triptans, its subcutaneous route bypasses gastrointestinal absorption, which can be advantageous during severe nausea.

Imigran S.C. should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use.

The medication is given as a single subcutaneous injection, typically into the thigh or abdomen, by a healthcare professional or trained individual following aseptic technique.

Serious risks include serotonin syndrome, coronary vasospasm, severe hypertension, and rare anaphylactic reactions. Patients should seek immediate medical attention if they experience chest pain, severe headache, or allergic symptoms.

Imigran S.C. is contraindicated in patients with known hypersensitivity to sumatriptan, uncontrolled hypertension, ischemic heart disease, peripheral vascular disease, or a history of hemiplegic or basilar migraine.